Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07524348
PHASE1

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Sponsor: Samsung Bioepis Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Official title: A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

149

Start Date

2026-03-23

Completion Date

2030-07

Last Updated

2026-05-11

Healthy Volunteers

No

Interventions

DRUG

E303

All participants will receive an intravenous (IV) infusion of E303

Locations (3)

Research Site

Scottsdale, Arizona, United States

Research Site

Fairfax, Virginia, United States

Research Site

Adelaide, Australia